Pepex Biomedical, Inc. has unveiled development of a next generation solution for insulin dependent diabetics which will combine regular glucose monitoring and insulin delivery for diabetes sufferers worldwide. The company is developing a complete product line of multi-function meters which allow simple testing of blood glucose levels and insulin delivery, appropriate to each glucose level measurement, all contained in a single, palm-sized unit. These meters provide anytime, anywhere tracking and treatment of diabetes.
Diabetes is a metabolic disorder in which the body’s blood glucose level is higher than normal due to insufficient amounts of a hormone called insulin or improper utilization of insulin available. Glucose is used as a source of fuel in the body to provide energy for our daily activities. However, when the body cannot maintain normal blood glucose levels it can have a serious impact on a person’s health. Unattended diabetes can lead to heart disease, blindness, kidney disease, degeneration of nerve fibers and, it is a major cause of premature illness and death.
According to the World Health Organization, approximately 285 million people, or 6.4% of the adult population, worldwide suffer from diabetes today. This figure is expected to increase to 438 million suffers by 2030. In order to fight the disease, diabetics are required to test their blood glucose levels multiple times daily and, those who are insulin dependent must administer insulin in an appropriate amount based upon the test results. Historically, this process requires a test meter, test strips, a lancet, syringes and a vial of insulin – an array of paraphernalia neither simple nor convenient to manage outside the home, while at work or during recreational activities.
“Pepex’s new line of simple, all in one meters can truly change the lives of diabetes sufferers worldwide,” comments Joseph Driver, Chairman of Pepex, “Our fully integrated device will test and track regular glucose levels and, in subsequent models, deliver the appropriate amount of insulin.”
Source : Pepex Biomedical, Inc.